Regulatory Intelligence, straight to your mailbox
Stay on top of Human Pharmacovigilance requirements with our monthly Regulatory Intelligence Reports.
Latest report May 2022
Safety Observer 189
The FDA published the final guidance for the electronic submission of Postmarketing Safety Reports.
This Plan includes three consecutive reports starting with the next release. The perfect solution to test the value of our service.
Starts at 180 €
This Plan includes eleven consecutive reports starting with the next release. Includes a double issue for July/August.
Starts at 600 €
Supporting the global Pharmacovigilance community since 2005
We are proud to serve pharmacovigilance professionals in more than 100 organisations across the world, including major pharma corporations, small biotech, service providers, and public hospitals.